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Imaging of angiogenesis is an important tool in the diag-
nosis of disease. Small molecule or nanoparticular probes
are currently developed to identify angiogenic endothelium
with non-invasive imaging techniques such as magnetic
resonance and ultrasound imaging. These techniques are
very valuable since they would not only contribute to
improved diagnosis, but will also allow monitoring of
angiogenesis intervention therapies, early detection of
disease, as well therapy development. Such techniques will
ultimately also contribute to the introduction of personal-
ized medicine. The current special issue of Angiogenesis is
put together to highlight several interesting and new
developments in this field.
Intervention in angiogenesis has currently made its way
into daily clinical practice. Several angiogenesis inhibitors
have been approved by the Food and Drug Administration
(FDA) for therapeutic use in the therapy of disease, most
commonly in oncological pathologies. Since angiogenesis
is a multidisciplinary theme, application of angiogenesis
inhibition is also expected for other angiogenic diseases
such as rheumatoid arthritis, atherosclerosis, endometriosis
and psoriasis [1]. Clinical application has been approved
for the therapy of many cancer types and eye diseases, such
as age-related macular degeneration. In the field of cancer,
neutralization of the key angiogenic growth factor VEGF is
daily clinical practice, mostly in combination with che-
motherapeutic agents. While the first approved agent,
Avastin/bevacizumab, is an anti-VEGF antibody based
therapeutic, later generation drugs are collectively based on
inhibition of VEGF (and other growth factor) signaling by
inhibition of tyrosine kinase inhibitors. This type of
inhibitors is now widely tested and clinical studies have led
to FDA approval for several of them. Application is pos-
sible now for many tumor types and is especially suc-
cessful in renal cell cancer, where monotherapy with
Sutent/sunitinib is nowadays first line therapy.
While these examples picture the exploitation of angi-
ogenesis for development of therapy, there is also an active
field of science exploiting angiogenesis or angiogenesis
inhibitors for diagnostic purposes making use of imaging
technologies. Imaging of diseased tissue by exploiting
vascular permeability or vascular targeting is a promising
tool in modern medicine. The latter approach depends on
identification of targets that are upregulated at angiogenic
blood vessels as compared to quiescent normal blood
vessels and on the availability of probes that bind selec-
tively and with high affinity to such targets. Different
genomic screening approaches, performed worldwide,
identified markers of angiogenic endothelial cells. Among
these markers are molecules such as avb3 integrin, CD13,
vimentin, VEGF receptor, and galectin-1, which have
shown promise in imaging of angiogenesis [2–4].
The field of angiogenesis research has been initiated by
the hypothesis that the growth of tumors is dependent on
the formation of new blood vessels, put forward by Folk-
man [5] in the early 1970s. This idea indicated that angi-
ogenesis inhibitors might be discovered and employed as
therapy against angiogenic diseases. The process of angi-
ogenesis is an intricately regulated cascade of processes
that occurs in growing tissues where, for example,
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conditions of hypoxia have turned on the production of
angiogenic growth factors such as the families of vascular
endothelial cell growth factors (VEGFs) and fibroblast
growth factors (FGFs). Preexisting endothelial cells in
capillaries can sense that and subsequently produce prote-
ases to dissolve the basement membrane and extracellular
matrix. Thereby endothelial cells migrate into the direction
of the stimulus. Endothelial cells subsequently proliferate
and form new vascular sprouts that become functional
blood vessels after the attraction of accessory cells such as
pericytes and the formation of a new rigid extracellular
matrix [6]. This angiogenesis cascade provides opportuni-
ties for intervention in every single step separately, and
inhibitors for each of these steps have been discovered and
are being developed in clinical studies. Anti-angiogenesis
compounds can specifically and directly inhibit the prolif-
eration of endothelial cells (TNP-470/caplostatin, platelet
factor-4) or interfere directly with the migratory activity of
these cells (endostatin, integrin antagonists). Alternatively,
they can inhibit the production or activity of metallopro-
teinases (MMPs), inducing a hampered mobility of endo-
thelial cells. However, the best developed angiogenesis
inhibitors are the ones that act indirectly, either by clearing
angiogenic growth factors from the circulation, blocking
the corresponding growth factor receptors, or by interven-
tion in the intracellular signaling pathways activated by
these growth factors.
A variety of imaging modalities is available to visualize
and characterize the angiogenic vasculature [7]. In a clin-
ical setting these include magnetic resonance imaging
(MRI), positron emission tomography (PET), single photon
emission computed tomography (SPECT), ultrasound
imaging and computed tomography (CT) [8]. Preclinically,
all the aforementioned imaging modalities are available,
but usually as dedicated small animal scanners with a
smaller field of view and higher spatial resolution [9]. In
addition, optical in vivo imaging techniques such as
intravital microscopy, near infrared fluorescence (NIRF)
and bioluminescence imaging are frequently employed to
evaluate angiogenesis in small laboratory animals [10].
Dynamic contrast enhanced (DCE) MRI is one of the
most widely and commonly used imaging methods to
visualize tumor angiogenesis in cancer patients and to
evaluate angiostatic therapies [11]. The application of
contrast enhanced CT imaging is also being explored for
perfusion imaging of cancers in patients. Both DCE MRI
and CT provide information about the vascular perme-
ability of tumors, but do not directly visualize the newly
formed vasculature. Fluorodeoxyglucose (FDG) PET
imaging allows quantitative imaging of glucose metabo-
lism. Since tumor glucose metabolism is expected to
decrease when nutrient vessels regress after the onset of
angiostatic therapy, as an indirect marker for angiogenesis,
a decrease in glucose metabolism may be visualized by
FDG-PET. Unfortunately, changes in vascular permeability
and FDG uptake may not necessarily be the result of
changes in ongoing angiogenesis, but can also be the result
of a variety of different processes, including hypoxia or the
collapse of the tumor microvasculature. More recently,
contrast enhanced MRI and CT as well as FDG-PET have
been explored for the study of neovascularization in ath-
erosclerosis in a number of studies [12, 13]. Although in its
infancy, these studies have shown a clear correlation
between atherosclerotic plaque permeability, microvessel
density and vulnerability. Interestingly, Calcagno et al.
[12], who also contributed to this special issue, have shown
parameters obtained in vivo with DCE-MRI and FDG-PET
to correlate with the plaque microvessel density determined
ex vivo, in a rabbit model of atherosclerosis.
To enable a more specific evaluation of angiogenesis,
target-specific imaging methods have been developed for
PET and SPECT imaging, MRI, ultrasound as well as
optical imaging [14]. Such molecular imaging methods
exploit probes that, after intravenous administration, spe-
cifically target molecular epitopes upregulated at the
angiogenic vasculature. These probes are labeled with
tracers and/or materials that allow their visualization with
one (or more) of the aforementioned imaging techniques.
The nuclear imaging techniques (PET and SPECT) inher-
ently rely on target-specific probes. To that end, targeting
ligands such as antibodies, proteins and peptides are
labeled with radioactive isotopes. Most notably, the avb3
integrin specific RGD peptide has been studied and applied
in both preclinical and clinical studies, which has resulted
in the development of a wide variety of radiolabeled RGD
analogs [15]. In addition, different other endothelial cell
markers have been exploited to image angiogenesis by PET
and SPECT, including the VEGF receptor or adhesion
molecules [16].
The development of nanoparticulate molecular imaging
probes has shown great progress in the past decade [17].
Such probes, carrying a high payload of contrast generating
materials, have shown to be especially useful for MR
molecular imaging of angiogenesis, since MRI is a rela-
tively insensitive technique that requires lM concentra-
tions of contrast agents to accumulate to allow their
visualization [18]. For optical techniques, quantum dots
have shown great potential because these semiconductor
nanoparticles exhibit some unique properties that make
them resistant to photobleaching and provide a very narrow
and tunable excitation wavelength [19]. Interestingly,
nanoparticles allow the integration of multiple materials
and agents for multimodal imaging purposes and/or the
combination of target-specific therapy [20].
For the current special issue on ‘‘Imaging of Angio-
genesis’’ we have invited a series of renowned expert
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investigators to contribute a state-of-the-art review. We
attempted to put together an issue that covers the above-
mentioned wide range of applications in this field. The
issue starts with a contribution, which also provided the
cover art, about vascular permeability and lymphatic
drainage imaging in experimental cancer by Vandoorne,
Addadi and Neeman [21]. Calcagno et al. [12] [22] show
the potential of contrast enhanced MR imaging to identify
the vulnerability of atherosclerotic plaques’. MRI of
angiogenesis in the brain as a result of stroke has been
reviewed by investigators of the NRM group of Dijkhuizen
in Utrecht, The Netherlands [23]. A contribution from a
Norwegian group by Hak et al. [24] exemplifies the use of
window chamber models to visualize nanoparticle target-
ing in tumors by intravital microscopy. We have contrib-
uted a mini review about paramagnetic quantum dots for
multimodal of tumor angiogenesis [25], while Snoeks,
Lo¨wik and Kaijzel from the Leiden University Medical
Center in The Netherlands highlight the latest develop-
ments in optical approaches to image and characterize
angiogenesis [26]. Investigators Jansen, Koutcher and
Shukla-Dave at Memorial Sloan-Kettering Cancer Center
[27] reviewed the field of head and neck squamous cell
carcinoma imaging. The Biomedical NMR group of the
Eindhoven University of Technology (Nicolay, Strijkers
et al.) summarized their work on multimodal lipoomes
[28], while Willmann et al. from Stanford University
School of Medicine wrote an overview of their ultrasound
based tumor angiogenesis imaging work [29]. The special
issue is wrapped up with a great contribution by Lanza
et al. [20] from Washington University of Medicine. They
give a summary of their work with angiogenesis specific
perfluorocarbon nanoparticles for molecular MRI and
therapy of cancer and atherosclerosis [30].
We are confident that this special issue of Angiogenesis
is a valuable documentation of the current technologies
available to image neovaculature formation.
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